| P50 | author | Giustino Varrassi | Q59556492 |
| | Alba Piroli | Q60311145 |
| | Antonella Paladini | Q77752484 |
| | Stefano Coaccioli | Q117194056 |
| P2093 | author name string | Sandro Carletti | |
| | Giuseppe Bentivegna | |
| P2860 | cites work | Chronic Pain in the Elderly: The Case for New Therapeutic Strategies | Q26782627 |
| | Failed back surgery syndrome: current perspectives | Q28070035 |
| | Neuropathic low back pain in clinical practice | Q28073412 |
| | Failed back surgery syndrome: diagnostic evaluation | Q28262467 |
| | Failed back surgery syndrome | Q28276143 |
| | The failed back surgery syndrome: reasons, intraoperative findings, and long-term results: a report of 182 operative treatments | Q28292792 |
| | Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis | Q31040290 |
| | The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. | Q33844609 |
| | Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy | Q34121827 |
| | A proposed autacoid mechanism controlling mastocyte behaviour | Q34290819 |
| | Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. | Q34636895 |
| | Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis | Q34640959 |
| | Control of pain initiation by endogenous cannabinoids. | Q34749934 |
| | The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors | Q34792462 |
| | Screening for neuropathic characteristics in failed back surgery syndromes: challenges for guiding treatment. | Q52838139 |
| | Gabapentin versus naproxen in the management of failed back surgery syndrome; a randomized controlled trial | Q58774151 |
| | Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain | Q60690696 |
| | Failed back surgery syndrome | Q83778363 |
| | Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs | Q84554587 |
| | Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study | Q87693527 |
| | Chronic pain and neurodegenerative processes in elderly people | Q95807705 |
| | Interactions between the immune and nervous systems in pain | Q34799654 |
| | Behavioral and cognitive-behavioral treatment for chronic pain: outcome, predictors of outcome, and treatment process | Q34999947 |
| | Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies | Q36365821 |
| | Microglia and neuropathic pain | Q37420652 |
| | Dual peripheral actions of immune cells in neuropathic pain | Q37828478 |
| | Thermosensitive polymeric micelles for targeted drug delivery | Q37935027 |
| | Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Sca | Q38010359 |
| | The role of the immune system in the generation of neuropathic pain | Q38019775 |
| | Cytokine modulation is necessary for efficacious treatment of experimental neuropathic pain | Q38067644 |
| | Interventional pain management for failed back surgery syndrome | Q38078503 |
| | Harnessing the anti-inflammatory potential of palmitoylethanolamide. | Q38222238 |
| | Degenerative Joint Diseases and Neuroinflammation. | Q39063573 |
| | Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. | Q39230043 |
| | Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. | Q39230971 |
| | Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. | Q39232701 |
| | Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. | Q42176106 |
| | Improvement in solubility of poor water-soluble drugs by solid dispersion | Q42496771 |
| | Strong analgesics: working towards an optimal balance between efficacy and side effects | Q43135082 |
| | Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced beta-hexosaminidase, serotonin and TNF alpha release from rat RBL-2H3 basophilic leu | Q43695333 |
| | Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. | Q44563709 |
| | Preventive Analgesia with Pregabalin in Neuropathic Pain from “Failed Back Surgery Syndrome”: Assessment of Sleep Quality and Disability | Q47934279 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1486010 | |
| P577 | publication date | 2017-08-10 | |
| P1433 | published in | Pain Research and Treatment | Q26842332 |
| P1476 | title | Palmitoylethanolamide in the Treatment of Failed Back Surgery Syndrome | |
| P478 | volume | 2017 | |